



Epstein-Barr virus (EBV)-associated smooth 
muscle tumors (EBV-SMT) are a recently recog-
nized distinctive group of mesenchymal tumors 
that develop exclusively in patients with clinical 
immunosuppression, predominantly in human 
immunodeficiency virus (HIV) infection/acquired 
immunodeficiency syndrome (AIDS), and solid 
organ transplantation [1-2]. Since clonal EBV is 
consistently detected in these tumors but not in 
conventional smooth muscle tumors occurring 
outside the setting of immunosuppression, EBV 
virus is believed to play an essential role in the 
tumorigenesis of EBV-SMT [3]. The molecular 
mechanism by which EBV drives the smooth 
muscle transformation is unclear, however re-
cent studies have suggested it is mediated, at 
least in part, through the activation of the Akt/
mammalian target of rapamycin (mTOR) signal-
ing pathway [4].   
 
In organ transplant recipients, EBV-SMT most 
often involve the lung, gastrointestinal tract, 
and liver [5]. In AIDS patients, visceral EBV-SMT, 
particularly those involving the liver are rare, 
and occur mostly in the pediatric population, 
with only eight cases reported thus far in adults 
[1, 6-12]. The predisposition to visceral EBV-
SMT in the pediatric HIV- infected population 
may be related to myocyte immaturity, whereas 
in HIV-infected adults, a mature visceral smooth 
muscle tissue may possess resistance to EBV 
infection or neoplastic transformation [13].  
 
Here we describe a new case of multifocal he-
patic EBV-SMT in a 34-year-old AIDS patient and 
investigate the activation status of the mTOR 
signaling in this tumor. In addition, we provide a 
review of the literature on the clinicopathologic 
findings of hepatic EBV-SMT in adult AIDS pa-
tients, and discuss their biologies and possible 




The patient is a 34-year-old man who was first 
diagnosed with HIV/AIDS in 2000. He presented 
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to our hospital in May 2010 with generalized 
fatigue, right upper quadrant abdominal pain 
and watery diarrhea for 3 months. The patient 
was initially placed on a regimen of highly active 
antiretroviral therapy (HAART) using tenofovir/
emtricitabine combination and efavirenz, which 
were discontinued 5 years prior to admission 
due to the fact that he did not tolerate the medi-
cations. He had a history of Pneumocystis ji-
roveci pneumonia, oral and genital herpes infec-
tions, and perianal abscess. On admission, 
physical examination was unrevealing. His 
CD4+ T cell count was 15 cells/ml and the 
plasma HIV-1 RNA viral load was 79,600 cop-
ies/ml. Liver function test showed elevated liver 
enzymes. The diarrhea was attributed to his 
chronic HIV infection and ultrasound of the ab-
domen revealed two hypoechoic lesions in the 
right and left hepatic lobes, measuring 1.9 cm 
and 2.0 cm in diameter, respectively. Follow-up 
abdominal computed tomography (CT) scan 
(Figure 1) showed five hypodense lesions, rang-
ing from 0.9 to 2.3 cm in greatest dimension, 
with minimal peripheral arterial enhancement 
throughout the liver. No extrahepatic masses 
were appreciated on the CT of chest, abdomen, 
and pelvis and in an magnetic resonance imag-
ing (MRI) of the brain. CT-guided percutaneous 
fine needle aspiration biopsy of the lesions in 
the right hepatic lobe was performed. The pa-
tient was restarted on HAART with tenofovir, 
emtricitabine, and darunavir/norvir combina-
tion, and his diarrhea improved after starting 
the antiretroviral therapy with the addition of 
loperamide. He was discharged and referred to 
the University of Texas MD Anderson Cancer 
Center for further management of his liver le-
sions. The patient was clinically stable, exhibit-
ing viral suppression in the latest follow-up at 7 
months after this presentation.  
 
Materials and methods 
 
Bright field microscopy 
 
Tissue was fixed in 10% formalin, embedded in 
paraffin, routinely processed, and stained with 
hematoxylin and eosin. Fite’s acid fast stain and 




Formalin-fixed, paraffin-embedded sections of 
tissue were deparaffinized and rehydrated. Sec-
tions were stained with the primary antibodies 
against smooth muscle actin (SMA) (DAKO, 
Carpinteria, CA), desmin (DAKO), CD34 (Becton 
Dickinson, Franklin Lakes, NJ), CD31 
(Novocastra, Newcastle upon Tyne, UK), human 
herpes virus 8 (HHV8) (Novocastra), S100 
(DAKO), CD117 (DAKO), CD99 (DAKO), CD21 
(DAKO), pan-cytokeratin cocktail (Novocastra), 
Ki-67 (DAKO), phosphorylated (p)-mTOR at ser-
ine 2448 (Cell Signaling, Beverly, MA), p-Akt at 
serine 473 (Cell Signaling), and EBV latent 
membrane protein 1 (EBV-LMP1) (DAKO). Those 
incubated with anti-phosphospecific probes 
were incubated at 4°C, per the vendor’s recom-
mended procedure; all other primary antibodies 
were incubated at room temperature. Sections 
were then stained with the biotinylated secon-
dary antibodies as previously described [14], 
and the antibody complexes were detected with 
the direct avidin-biotin-peroxidase method 
(Dako), using 3, 3’-diaminobenzidine as the 
chromogen and hematoxylin as the counter-
stain. Positive and negative controls were run in 
parallel with the samples. 
 
Chromogenic in situ hybridization for EBV-
encoded small RNA 1 (EBER-1) 
 
Formalin-fixed, paraffin-embedded sections of 
tissue were mounted on slides treated with 3-
aminopropyltriethoxysilane, deparaffinized, di-
gested with proteinase K, and dehydrated. The 
EBER-1 probe (Operon Technologies Inc, San 
Figure 1. Contrast-enhanced computed tomography 
(CT) scan of the abdomen shows multiple hypodense 
lesions (arrow), 0.9 to 2.3 cm in maximal dimension, 
with minimal peripheral arterial enhancement 
throughout the liver. 
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Pablo, Ca), an oligonucleotide probe that de-
tects a non-poly(A) RNA EBV transcript ex-
pressed in latently infected cells, was applied. 
The slides were incubated at 37°C for 1 hour 
before being washed with probe wash, devel-
oped with an in situ hybridization detection sys-
tem (Biomeda, Foster City, CA), and counter-




A literature search was performed from 1990 to 
February 2011 on PubMed using the search 
terms of “liver”, “Epstein-Barr virus”, “HIV infec-
tion”, “acquired immunodeficiency syndrome”, 
“smooth muscle tumor”, “leiomyoma”, 
“leiomyosarcoma”, and “muscle neoplasms”. All 
reported cases with diagnoses of EBV associ-
ated SMT in the liver were reviewed. Only cases 
of adult HIV-infected patients (≥ 18 years old) 
were included, excluding the pediatric cases. A 
total of 9 cases of intrahepatic EBV-SMT in adult 
AIDS patients, including our current case, ful-





Microscopic and Immunohistochemical 
findings 
 
On light microscopy (Figure 2), these hypercellu-
lar hepatic lesions are comprised of two cell 
populations: relatively monomorphic spindle 
cells arranged in short intersecting fascicles, 
and more primitive-looking oval to round cells 
Figure 2. Histologic fea-
tures of EBV-SMT. A. The 
tumors contain two cell 
populations composed of 
spindle cells arranged in 
short fascicles and oval to 
round cells forming dis-
tinct nodules. B. The spin-
dle cells have elongated 
blunt-ended nuclei and 
abundant eosinophilic 
cytoplasm. C. The oval-
round cells show mild to 
moderate nuclear atypia. 
D. Hemangiopericytoma-
like vascular pattern is 
focally present.  
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that form separate nodules. The nuclei of the 
tumor cells are slightly hyperchromatic with deli-
cate chromatin and inconspicuous nucleoli. The 
cytoplasm was deeply eosinophilic. There were 
mild to moderate nuclear atypia with a minimal 
mitotic activity of 1 mitotic figure per 10 high 
power fields. Focal single cell necrosis was 
seen. Additionally, some tumor cells were inti-
mately related to the walls of small blood ves-
sels, suggesting smooth muscle cells in the pre-
existing vessels as the potential origin of the 
lesions. The residual non-neoplastic hepatic 
parenchyma showed intact architecture with no 
evidence of cirrhosis.   
 
Immunohistochemical stains demonstrated that 
the tumor cells were diffusely positive for SMA, 
focally positive for desmin (Figure 3), and nega-
tive for CD34, CD31, HHV8, S100, CD117, 
CD99, and pan-cytokeratin. The proliferation 
marker Ki-67 highlighted only a few proliferating 
tumor cells (Figure 3). Fite’s acid fast stain and 
Warthin-Starry stain failed to demonstrate the 
presence of mycobacteria or Bartonella hense-
lae microorganisms, as are seen in the myco-
bacterial spindle cell pseudotumor and bacillary 




EBV was studied by chromogenic in situ hybridi-
zation using EBER1 oligonucleotides. The nuclei 
of the tumor cells showed strong positivity for 
EBER-1 in greater than 95% of the cells, indicat-
Figure 3. A. Immunohis-
tochemical stain for 
smooth muscle actin 
produces strong diffuse 
cytoplasmic staining in 
the tumor cells. B. The 
tumor cells show focal 
immunoreactivity for 
desmin. C. EBER in situ 
hybridization produces 
strong distinct nuclear 
staining in the tumor 
cells. D. Ki-67 immu-
nostain highlights a few 
proliferating tumor cells.    
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ing latent EBV viral infection (Figure 3). There 
was no in situ hybridization signal in the nuclei 
of the adjacent hepatocytes. Immunohisto-
chemical stain of EBV-LMP1 was negative in 
tumor cells. CD21, the EBV receptor on B lym-
phocytes, could not be detected in the tumor 
cells by immunostaining. Polymerase chain re-
action (PCR) analysis of the patient’s plasma 
failed to detect the presence of EBV DNA. A di-
agnosis of EBV-associated smooth muscle tu-
mor with uncertain malignant potential was 
made.  
 
Studies on Akt/mTOR signal pathway 
 
The chromogenic signals for p-Akt (serine 473) 
and p-mTOR (serine 2448) were both primarily 
localized in the nuclei of the tumor cells. Moder-
ate to strong nuclear staining of p-Akt and p-
mTOR was observed in > 90% of tumor cells, 
indicating constitutive activation of the mTOR 




The clinicopathologic findings of the current and 
8 previously reported cases of hepatic EBV-SMT 
occurring in HIV-infected adults are summarized 
in Tables 1 and 2. The male to female ratio was 
8: 1, and 8 of 9 patients were in their third dec-
ade of life. Hepatic EBV-SMT were detected 
from 48 to 120 months (mean 96 months) after 
the diagnosis of HIV infection. CD4 cell count at 
the initial presentation ranged from 2 to 150 
cells/ul (mean 39 cells/ul; median 18 cells/ul). 
Plasma HIV RNA levels were extremely variable 
ranging from < 400 to 796,000 copies/ml. The 
hepatic tumors can be single or multiple, with a 
maximal diameter varying greatly between 0.9 
cm and 14.0 cm. Follow-up information was 
available in eight patients. Five patients were 
alive: one patient (case 9) underwent resection 
of the liver tumors and had no recurrence 8 
months post surgery, whereas the remaining 
four receiving no treatment were alive with per-
sistent liver tumors at least 7, 7, 11, and 12 
months after presentation. Three patients died. 
Of note, only one patient (case 8) died of EBV-
SMT nine months following diagnosis, whereas 
the other two died of opportunistic infections. 
This patient (case 8) had a very high tumor bur-
den with SMT involving multiple organs includ-
ing the liver, lungs, gallbladder, and spinal cord. 
Regarding microscopic features, mitotic activity 
was documented in 7 of 9 cases, with virtually 
all 7 cases having less than 3 mitoses per 10 
high power fields. Focal necrosis was present in 
2 cases.  
 
Together, the observations in these 9 cases 
suggest that hepatic EBV-SMT usually present 
as relatively well-differentiated tumors in adult 
HIV patients. The natural evolution of these tu-
mors appears to be slow, and even in the face 
of multiple lesions, death in these patients is 
only occasionally due to the direct effects of 
EBV-SMT. Accordingly, it is very important to 
distinguish hepatic EBV-SMT from the non-EBV-
related primary or metastatic leiomyosarcomas 
that occur in the liver, which typically pursue a 
far more aggressive clinical course and may 
potentially necessitate different clinical man-
Figure 4. Expression of p-Akt at serine 473 (A) and p-mTOR at serine 2448 (B) in the current case of hepatic EBV-
SMT.  
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agement [15-16].    
 
EBV-SMT has many unique biological and his-
tologic features that are rarely seen in the non-
EBV-related SMT. These include occurrence 
exclusively in immunosuppressed patients, fre-
quent multifocal involvement at very uncommon 
sites, presence of dual cell populations com-
posed of not only the typical spindle-shaped 
cells but also primitive-appearing oval to round 
cells, hemangiopericytoma-like vascular pattern, 
variable intratumoral T lymphocytes, only mild 
to moderate nuclear atypia, and consistently 
sparse mitotic activity [11], [17]. The presence 
of multifocal masses, as seen in our patient, 
certainly raises the concern for malignancy and 
metastases. However, previous molecular analy-
sis of different tumors in a given patient have 
shown that each tumor is derived from a differ-
ent clone and therefore, represents multiple 
independent primaries rather than metastases 
from a single tumor [11], [2], [1]. Clonal analy-
sis was not performed in the current case. Im-
munohistochemical stain for SMA and EBER in 
situ hybridization are diffusely positive in all EBV
-SMT examined thus far, and are currently used 
as the most sensitive and reliable markers for 
the diagnosis of EBV-SMT. Expression of desmin 
is variable in EBV-SMT.    
 
At present, how EBV infects and transforms the 
myocytes is largely unknown. Immunostaining 
for CD21, the EBV receptor on B lymphocytes 
and epithelial cells [18], was negative in the 
current case, similar to the findings of other 
investigators [7-8]. In contrast, McClain et al 
reported strong staining of CD21 in all 6 cases 
of EBV-SMT in HIV-infected children [1] , [19]. 
These discrepancies may reflect different anti-
bodies utilized in immunohistochemistry or 
lower expression of CD21 in some cases that is 
below the threshold of technique sensitivity. 
Alternatively, EBV may enter the myocytes via 
other routes, such as fusion with EBV-infected 
lymphocytes [20-21]. Recently, a novel EBV re-
ceptor was identified in EBV-associated gastric 
carcinoma cells [22], raising the possibility that 
EBV-SMT tumor cells may similarly express a 
receptor protein that is distinct from CD21. EBV-
LMP1 has clearly established transforming 
Abbreviations: NA = not available; Ref. = reference number; M = male; F = female; S = single nodule; M = multiple 
nodules; Tx = treatment 
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properties [23-24]. However, reports on LMP1 
expression in EBV-SMT are equivocal, with nega-
tive immunostaining observed in the vast major-
ity of cases, including the present case, focal 
faint reactivity in three cases, and detection by 
reverse transcriptase-polymerase chain reaction 
(RT-PCR) but not by immunohistochemistry in 
two cases [25], [11], [26]. Thus, the role of 
LMP1 in EBV-SMT remains to be determined.    
 
Due to the relative rarity, the malignant poten-
tial of EBV-SMT is uncertain, revealing neither 
the benign behavior of leiomyomas nor the ap-
parently aggressive behavior of leiomyosarco-
mas. Accordingly, optimal treatment for EBV-
SMT aside from surgery is yet to be determined. 
Currently, complete surgical resection remains 
the mainstay therapy and has been shown satis-
factory results, as in case 9 of our review [27]. 
Chemotherapy and radiotherapy appear to be 
ineffective in these tumors. Improvement of 
immune status, which is effective in the treat-
ment of EBV-related posttransplant lymphopro-
liferative disease, might also improve the out-
come of EBV-SMT in AIDS patients [10]. 
The mammalian target of rapamycin (mTOR) 
has a central role in the regulation of cell growth 
[28]. Various growth factors and nutrients acti-
vate mTOR via multiple signaling pathways, 
which in turn stimulate protein synthesis by 
phosphorylating key translation regulators such 
as ribosomal S6 kinase and eukaryote initiation 
factor 4E binding protein 1 [29]. High levels of 
dysregulated mTOR activity are associated with 
many human diseases, including tumorigenesis. 
Studies by Sodhi [30] and Stallone [31] et al 
revealed that activation of the Akt/mTOR signal 
pathway played an essential role in AIDS-related 
Kaposi sarcoma’s tumorigenesis, and sirolimus, 
an mTOR inhibitor, blocked the progression of 
Kaposi sarcoma. Very recently, overactivation of 
the Akt/mTOR signaling was also detected in 
EBV-SMT [4]. In one transplant patient, si-
rolimus induced complete remission of EBV-
SMT in the liver [32]. Interestingly, Wittek et al 
published data demonstrating a close relation-
ship between cultured Kaposi sarcoma cells 
from AIDS patients and leiomyoblasts [33]. In 
our case, the Akt-mTOR signal pathway is consti-
tutively activated and more importantly the ex-
Abbreviations: HPFs = high power fields; NA = not available; Ref. = reference number; IHC = immunohistochemistry; 
ISH = in situ hybridization; HPC = hemangiopericytoma; LMP = low malignant potential; UMP = unknown malignant 
potential 
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pression is mainly nuclear. The nuclear subcom-
partmentalization of p-mTOR (Ser 2448) and its 
putative downstream effector, p-Akt (Ser 473) 
more likely reflects mTOR complex 2 (mTORC2) 
activation, which is less responsive to inhibition 
by rapamycin (sirolimus) [34]. The mechanism 
of rapamycin antitumorigenic effect in such 
cases needs further study. Specifically, further 
studies are needed to investigate the possible 
etiologic relationship between EBV-SMT and 
Kaposi sarcoma, to examine additional thera-
peutic molecular strategies aimed at inhibiting 
this Akt/mTOR pathway, and to search for other 
alternative explanations for the efficacy of si-
rolimus in EBV-SMT cases.  
 
In conclusion, we have described a case of mul-
ticentric hepatic EBV-SMT affecting an adult 
patient with AIDS and examined the activation 
of the mTOR signal pathway in this tumor. A 
review of the literature suggests that the behav-
ior of such tumors appears far less aggressive 
than the non-EBV- related primary or metastatic 
leiomyosarcomas involving the liver. Given the 
increased incidence and prolonged survival of 
AIDS patients, hepatic EBV-SMT are expected to 
be encountered more frequently in the future. 
This case demonstrates that EBV-SMT need to 
be included in the differential diagnoses of liver 
mass(es) in HIV-infected patients and that SMA 
immunohistochemistry and EBER in situ hybridi-
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